Stevanato Group’s (STVN) Outperform Rating Reiterated at William Blair

William Blair reaffirmed their outperform rating on shares of Stevanato Group (NYSE:STVN) in a research report report published on Friday,RTT News reports. William Blair also issued estimates for Stevanato Group’s Q1 2026 earnings at $0.13 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.17 EPS and Q4 2026 earnings at $0.23 EPS.

A number of other brokerages have also commented on STVN. Wolfe Research assumed coverage on Stevanato Group in a research report on Friday, December 13th. They issued an “outperform” rating and a $28.00 price objective on the stock. Bank of America raised their price target on Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Morgan Stanley restated an “equal weight” rating and issued a $23.00 price target (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Finally, UBS Group reduced their price target on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating on the stock in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of €27.75 ($30.16).

Stevanato Group Trading Up 4.9 %

STVN stock opened at €21.72 ($23.61) on Friday. The business has a fifty day moving average price of €21.38 and a 200 day moving average price of €20.55. Stevanato Group has a fifty-two week low of €16.56 ($18.00) and a fifty-two week high of €33.49 ($36.40). The stock has a market capitalization of $6.58 billion, a price-to-earnings ratio of 46.21, a P/E/G ratio of 7.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21.

Stevanato Group (NYSE:STVN) last released its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting analysts’ consensus estimates of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The firm had revenue of €352.68 million during the quarter, compared to analysts’ expectations of €346.26 million. Analysts expect that Stevanato Group will post 0.5 EPS for the current fiscal year.

Institutional Trading of Stevanato Group

Several hedge funds and other institutional investors have recently modified their holdings of STVN. Zions Bancorporation N.A. acquired a new stake in shares of Stevanato Group in the 3rd quarter valued at about $1,049,000. Sivik Global Healthcare LLC acquired a new stake in shares of Stevanato Group in the 3rd quarter valued at about $2,800,000. King Wealth Management Group raised its stake in shares of Stevanato Group by 30.2% in the 3rd quarter. King Wealth Management Group now owns 94,800 shares of the company’s stock valued at $1,896,000 after purchasing an additional 22,000 shares during the period. Royce & Associates LP increased its position in shares of Stevanato Group by 45.8% in the third quarter. Royce & Associates LP now owns 343,159 shares of the company’s stock valued at $6,863,000 after acquiring an additional 107,869 shares during the last quarter. Finally, Natixis Advisors LLC increased its position in shares of Stevanato Group by 20.3% in the third quarter. Natixis Advisors LLC now owns 51,343 shares of the company’s stock valued at $1,027,000 after acquiring an additional 8,669 shares during the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.